Stiripentol – characteristic of a new antiepileptic drug

Bibliography

• Czuczwar SJ, Patsalos PN. The new generation of GABA enhancers. CNS Drugs 2001;15:339-50
   PubMed Web of Science ®Google Scholar
• Willmore LJ. Clinical pharmacology of new antiepileptic drugs. Neurology 2000;55(Suppl 3):17-24
   Google Scholar
• Stepien K, Tomaszewski M, Czuczwar SJ. Profile of anticonvulsant activity and neuroprotective effects of novel and potential antiepileptic drugs – an update. Pharmacol Rep 2005;57:719-33
   PubMed Web of Science ®Google Scholar
• Meldrum BS. Update on the mechanism of action of antiepileptic drugs. Epilepsia 1996;37(Suppl 6):S4-11
   PubMedGoogle Scholar
• Astoin J, Mariwain A, Riveron A, et al. Influence of novel alpha-ethylene alcohols on the central nervous system. Eur J Med Chem 1978;13:41-7
   Web of Science ®Google Scholar
• Chollet DF. Determination of antiepileptic drugs in biological material. J Chromatogr 2002;767:191-223
   Google Scholar
• Shen DD, Levy RH, Savitch JL, et al. Comparative anticonvulsant potency and pharmcokinetics of (+)- and (-)-enantiomers of stiripentol. Epilepsy Res 1992;12:29-36
   PubMed Web of Science ®Google Scholar
• Czapinski P, Blaszczyk B, Czuczwar SJ. Mechanisms of action of antiepileptic drugs. Curr Top Med Chem 2005;5:3-14
   PubMed Web of Science ®Google Scholar
• Poisson M, Huguet F, Savattier A, et al. A new type of anticonvulsant – stiripentol. Arzneimittelforschung 1984;34:199-204
   PubMed Web of Science ®Google Scholar
• Wegeman R, Ilies A, Aurousseau M, Patte F. Pharmacocellular enzymology of the mode of action of the stiripentol during the cardiozolic epilepsy. The metabolism of lipids, proteins, nucleoproteins and proteoglycans. Cell Mol Biol 1978;23:455-80
   Web of Science ®Google Scholar
• Bialer M, Johannessen SI, Kupferberg HJ, et al. Progress report on new antiepileptic drugs: a summary report of the Eight Eilat Conference (Eilat VIII). Epilepsy Res 2007;73:1-52
   PubMed Web of Science ®Google Scholar
• Quilichini PP, Chiron C, Ben-Ari Y, Gozlan H. Stiripentol, a putative GABA-ergic drug, enhances the duration of opening of GABAA-receptor channels. Epilepsia 2006;47:704-16
   PubMed Web of Science ®Google Scholar
• Shen DD, Levy RH, Moor MJ, Savitch JL. Efficacy of stiripentol in the intravenous pentylenetetrazol infusion seizure model in the rat. Epilepsy Res 1990;7:40-8
   PubMed Web of Science ®Google Scholar
• Luszczki JJ, Ratnaraj N, Patsalos PN, Czuczwar SJ. Characterization of the anticonvulsant, behavioral and pharmacokinetic interaction profiles of stiripentol in combination with clonazepam, ethosuximide, phenobarbital, and valproate using isobolographic analysis. Epilepsia 2006;47:1841-54
   PubMed Web of Science ®Google Scholar
• Gasior M, Ungard JT, Witkin JM. Preclinical evaluation of newly approved and potential antiepileptic drugs against cocaine-induced seizures. J Pharmacol Exp Ther 1999;290:1148-56
   PubMed Web of Science ®Google Scholar
• Luszczki JJ, Czuczwar SJ. Biphasic characteristic of interactions between stiripentol and carbamazepine in the mouse maximal electroshock-induced seizure model: a three-dimensional isobolographic analysis. Naunyn-Schmiedeb Arch Pharmacol 2006;374:51-64
   Google Scholar
• Pieri F, Wegmann R, Astoin J. Pharmacokinetic study of 3H-stiripentol in rats. Eur J Drug Metab Pharmacokinet 1982;7:5-10
   PubMed Web of Science ®Google Scholar
• Sawchuk RJ, Zaske DE, Cipolle RJ, et al. Kinetic models for gentamicin dosing with the use of individual patient parameters. Clin Pharmacol Ther 1977;21:362-9
   PubMed Web of Science ®Google Scholar
• Lin HS, Levy RH. Pharmacokinetic profile of a new anticonvulsant stiripentol in the Rhesus monkey. Epilepsia 1983;24:692-702
   PubMed Web of Science ®Google Scholar
• Tang C, Zhang K, Lepage F, et al. Metabolic chiral inversion of stiripentol in the rat. Drug Metab Dispos 1994;22:554-60
   PubMed Web of Science ®Google Scholar
• Zhang K, Lepage F, Rashed M, Baillie TA. Stereoselective disposition of stiripentol in the rat. Pharmacologist 1991;33:234
   Google Scholar
• Loiseau P, Duche B. Stiripentol. In: Antiepileptic Drugs. 3rd edition. Levy RH, Mattson RM, Meldrum BS, et al., editors. New York: Raven Press; 1988; p. 955-69
   Google Scholar
• Finnel RH, Bennett GD, Mather GG, et al. Effect of stiripentol dose on phenytoin-induced teratogenesis in a mouse model. Reprod Toxicol 1999;13:85-91
   PubMed Web of Science ®Google Scholar
• Luszczki JJ, Czuczwar SJ. Isobolographic and subthreshold methods in the detection of interactions between oxcarbazepine and conventional antiepileptics – a comparative study. Epilepsy Res 2003;56:27-42
   PubMed Web of Science ®Google Scholar
• Stiripentol. BCX 2600. Drugs RD 2002;3:220-2
   PubMedGoogle Scholar
• Perez J, Chiron C, Musial C, et al. Stiripentol: efficacy and tolerability in children with epilepsy. Epilepsia 1999;40:1618-26
   PubMed Web of Science ®Google Scholar
• Thanh TN, Chiron C, Dellatolas G, et al. Long-term efficacy and tolerance of stiripentol in severe myoclonic epilepsy of infancy (Dravet's syndrome). Arch Pediatr 2002;9:1120-7
   PubMed Web of Science ®Google Scholar
• Chiron C, Marchand MC, Tran A, et al. Stiripentol in severe myoclonic epilepsy in infancy: a randomized placebo-controlled syndrome-dedicated trial. STILCO study group. Lancet 2000;356:1638-42
   PubMed Web of Science ®Google Scholar
• Kassai B, Chiron C, Augier S, et al. Severe myoclonic epilepsy in infancy: a systematic review and a meta-analysis of individual patient data. Epilepsia 2007: published online Nov 19, doi:10.1111/j.1528-1167.2007.01423.x
   PubMedGoogle Scholar
• Chiron C, Tonnelier S, Rey E, et al. Stiripentol in childhood partial epilepsy: randomized placebo-controlled trial with enrichment and withdrawal design. J Child Neurol 2006;21:496-502
   PubMed Web of Science ®Google Scholar
• Farwell JR, Anderson GD, Kerr BM, et al. Stiripentol in atypical absence seizures in children. An open trial. Epilepsia 1993;34:305-11
   PubMed Web of Science ®Google Scholar
• Loiseau P, Strube E, Tor J, et al. Neurophysiological and therapeutic evaluation of stiripentol in epilepsy. Preliminary results. Rev Neurol (Paris) 1988;144:165-72
   PubMed Web of Science ®Google Scholar
• Levy RH, Loiseau P, Guyot M, et al. Michaelis-Menten kinetics of stiripentol in normal humans. Epilepsia 1984;25:486-91
   PubMed Web of Science ®Google Scholar
• Levy RH, Lin HS, Blehaut HM, Tor JA. Pharmacokinetics of stiripentol in normal man: evidence of nonlinearity. J Clin Pharmacol 1983;23:523-33
   PubMed Web of Science ®Google Scholar
• Walker MC, Patsalos PN. Clinical pharmacokinetics of new antiepileptic drugs. Pharmacol Ther 1995;67:351-84
   PubMed Web of Science ®Google Scholar
• Levy RH, Loiseau P, Guyot M, et al. Stiripentol kinetics in epilepsy: nonlinearity and interactions. Clin Pharmacol Ther 1984;36:661-9
   PubMed Web of Science ®Google Scholar
• Moreland TA, Astoin J, Lepage F, et al. The metabolic fate of stiripentol in man. Drug Metab Dispos 1986;14:654-62
   PubMed Web of Science ®Google Scholar
• Kerr BM, Martinez-Lage JM, Viteri C, et al. Carbamazepine dose requirements during stiripentol therapy: influence of cytochrome P-450 inhibition by stiripentol. Epilepsia 1991;32:267-74
   PubMed Web of Science ®Google Scholar
• Mesnil M, Testa B, Jenner P. In vitro inhibition by stiripentol of rat brain cytochrome P-450-mediated naphthalene hydroxylation. Xenobiotica 1988;18:1097-106
   PubMed Web of Science ®Google Scholar
• Tran A, Rey E, Pons G, et al. Influence of stiripentol on cytochrome P450-mediated metabolic pathways in human: in vitro and in vivo comparison and calculation of in vivo inhibition constants. Clin Pharmacol Ther 1997;62:490-504
   PubMed Web of Science ®Google Scholar
• Mather GG, Bishop FE, Trager WF, et al. Mechanisms of stiripentol interactions with carbamazepine and phenytoin. Epilepsia 1995;36(Suppl 3):162
   Web of Science ®Google Scholar
• Bebin M, Bleck TP. New anticonvulsant drugs. Focus on flunarizine, fosphenytoin, midazolam and stiripentol. Drugs 1994;48:153-71
   PubMed Web of Science ®Google Scholar
• Levy RH, Loiseau P, Guyot M. Effects of stiripentol on valproate plasma levels and metabolism. Epilepsia 1987;28:605
   Google Scholar
• Pisani F. Influence of co-medication on the metabolism of valproate. Pharm Weekbl Sci 1992;14:108-13
   PubMedGoogle Scholar
• Levy RH, Rettenmeier AW, Anderson GD, et al. Effects of polytherapy with phenytoin, carbamazepine and stiripentol on formation of 4-ene-valproate, a hepatotoxic metabolite of valproic acid. Clin Pharmacol Ther 1990;48:225-35
   PubMed Web of Science ®Google Scholar
• Rey E, Tran A, d'Athis P, et al. Stiripentol potentiates clobazam in childhood epilepsy: a pharmacological study. Epilepsia 1999;40(Suppl 7):112-3
   Google Scholar
• Giraud C, Treluyer JM, Rey E, et al. In vitro and in vivo inhibitory effect of stiripentol on clobazam metabolism. Drug Metab Dispos 2006;34:608-11
   PubMed Web of Science ®Google Scholar
• Giraud C, Tran A, Rey E, et al. In vitro characterization of clobazam metabolism by recombinant cytochrome P450 enzymes: importance of CYP2C19. Drug Metab Dispos 2004;32:1279-86
   PubMed Web of Science ®Google Scholar
• Kröll-Seger J, Portilla P, Dulac O, Chiron C. Topiramate in the treatment of highly refractory patients with Dravet syndrome. Neuropediatrics 2006;37:325-9
   PubMed Web of Science ®Google Scholar
• Guerrini R, Dravet C, Genton P, et al. Lamotrigine and seizure aggravation in severe myoclonic epilepsy. Epilepsia 1998;39:508-12
   PubMed Web of Science ®Google Scholar
• Lortie A, Chiron C, Dumas C, et al. Optimizing the indication of vigabatrin in children with refractory epilepsy. J Child Neurol 1997;12:253-9
   PubMed Web of Science ®Google Scholar
• Wallace SJ. Myoclonus and epilepsy in childhood: a review of treatment with valproate, ethosuximide, lamotrigine and zonisamide. Epilepsy Res 1998;29:147-54
   PubMed Web of Science ®Google Scholar
• Trojnar MK, Wojtal K, Trojnar MP, Czuczwar SJ. Stiripentol. A novel antiepileptic drug. Pharmacol Rep 2005;57:154-60
   PubMed Web of Science ®Google Scholar
• Chiron C. Stiripentol. Expert Opin Investig Drugs 2005;14:905-11
   PubMed Web of Science ®Google Scholar
• Chiron C. Stiripentol. Neurotherapeutics 2007;4:123-5
   PubMed Web of Science ®Google Scholar